Multiple innovative pharmaceutical companies迎盈利拐点

NightAirdropper · 2026-02-28T08:01:46+00:00

As of February 27, 24 innovative drug companies have released their 2025 performance briefings, with 79.17% achieving positive net profit growth. BeiGene has turned a profit for the first time, earning 1.422 billion yuan, and Microchip Biotech has shifted from loss to profit. Experts point out that the industry is showing signs of differentiation; although there is a positive trend, the overall recovery is still underway.

NightAirdropper

2026-02-28 08:01:46

Abstract generation in progress

Gelonghui, February 28 — According to Securities Daily and data from Eastmoney Choice, as of 4:00 PM on February 27, 24 innovative drug companies had released their 2025 performance forecasts, with 19 reporting positive net profit growth, accounting for 79.17%. Among them, BeiGene achieved its first full-year profit in 2025, with a net profit attributable to shareholders of 1.422 billion yuan; Microbio reported a net profit attributable to shareholders of 51.0757 million yuan in 2025, turning losses into gains. Senior investment advisor Yu Xiaoming from Jufeng Investment Consulting stated that the profit turning point for domestic innovative drug companies has preliminarily appeared, with leading companies showing strong profitability certainty. However, industry differentiation is evident, and the entire sector has not yet fully escaped the loss cycle. Overall, it remains in a recovery period characterized by narrowing losses, breakthroughs among top companies, and an overall positive trend, but the foundation is still not solid.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.